TORONTO, Results from an interim analysis of the Phase III RE-VERSE AD™ patient study demonstrate that 5 g of idarucizumab* immediately reversed the anticoagulant effect of dabigatran (Pradaxa ® ...
Ingelheim, Germany., Today, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending European approval of ...
Ingelheim, Germany, 26. November 2015 – The European Commission has approved Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa® (dabigatran ...
New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans
Idarucizumab, which was granted Breakthrough Therapy Designation by the FDA, was shown to restore the blood clotting mechanism in healthy volunteers1,2 This is the first time that such an effect was ...
Idarucizumab (Praxbind, Boehringer Ingelheim) reversed the anticoagulant effect of dabigatran (Pradaxa, Boehringer Ingelheim) in more than 98% of patients with life-threatening bleeding or who were ...
RIDGEFIELD, Conn., May 4, 2018 /PRNewswire/ -- Today, Boehringer Ingelheim announced that Praxbind® (idarucizumab), a specific reversal agent for Pradaxa® (dabigatran etexilate mesylate), is now ...
Three NOAC antidotes have been investigated: idarucizumab (Praxbind, approved by the FDA); andexanet alfa (andexanet, Biologics License Application under FDA review), and ciraparantag (in phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback